L. Moretti, G. Perugi - Vol. 7, Dicembre 2001, num.4
Testo Bibliografia Summary Riassunto Indice
Gli antipsicotici atipici nelle sindromi
psico-comportamentali secondarie a disturbi neurologici
Atypical antipsychotics in psychobehavioural
syndromes due to neurological disorders
1 Rao V, Lyketsos C. Delusions in Alzheimer's disease: a revicw. J Neuropsychiatry Clin Neurosci 1998;10:373-82.
2 Wragg R, Jeste D. Overview of depression and psychosis in Alzheimer's disease. Am J Psychiatry 1989;146:577-87.
3 Mega M, Cumnings J, Fiorello T. The spectrum of behavioral changes in Alzheimer's discase. Neurology 1990;1:65-73.
4 Chen Y, Stern Y, Sano M, Mayeux R. Cumulative risks of developing extrapyramidal signs, psychosis or myoclonus in the course of Alzheimer's disease. Arch Neurol 1991;48:1141-3.
5 Devanand D, Jacobs D, Tang M. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry 1997;54:257-63.
6 McKeith I, Perry R, Fairbairn A, Jabeen S, Perry E. Operational criteria for senile dementia of Lewy body type (SDLT). Psychol Med 1192;22:911-22.
7 Levy M, Miller B, Cummings J, Fairbanks L, Craig A. Alzheimer disease and frontotemporal dementias: behavioral distinctions. Arch Neurol 1996;53:687-90.
8 Cummings J. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991;39:708-16.
9 Naimark D, Jackson E, Rockwell E, Jeste DV. Psychotic symptorns in Parkinson's disease patients with dementia. Am Geriatr Soc 1996;44:296-9.
10 Sweet R, Mulsant B, Gupta B. Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life. Arch Gen Psychiatry 1995;52:478-86.
11 Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991;41:369-71.
12 Physicians' Desk Reference. Montvale N. Medical Economics 1998.
13 Alvir J, Lieberman J. Agranulocytosis: incidence and risk factors. J Clin Psychiatry 1994;55:137-8.
14 Fulton B, Goa K. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997;53:281-98.
15 Tran P, Deliva M, Tollefson G. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia [published erratum appears in J Clin Psychiatry 1997;58:275] J Clin Psychiatry 1997;58:205-11.
16 Gupta S, Droney T, Al-Samarrai S, Keller P, Frank B. Olanzapine-induced weight gain. Ann Clin Psychiatry 1998;10:39.
17 Owens D. Extrapyramidal side effects and tolerability of risperidone: a review. J Clin Psychiatry 1994;55:29-35.
18 Raheja R, Bharwani I, Penetrante AE. Efficacy of risperidone for behavioral disorders in the elderly: a clinical observation. J Geriatr Psychiatry Neurol 1995;8:159-61.
19 Lacro J, Jeste D. Geriatric psychosis. Psychiatr Q 1997;68:247-60.
20 Leucht S, Pitschell-Walz, Abraham D, Kissling W. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone and sertindole compared to convential antipsychotics and placebo. A meta analysis of randomized controlled trials. Schizoph Res 1998;35:51-68.
21 Christenson R, Blazer D. Epidemiology of persecutory ideation in an elderly population in the community. Am J Psychiatry 1984;141:1088-91.
22 DSM IV American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Ed. Washington, DC: 1994.
23 Jeste D, Harris M, Krull A. Clinical and neuropsychological characteristics of patients with late-onset schizophrenia. Am J Psychiatry 1995;152:722-30.
24 Satterlee W, Tollefson G, Reams S. A clinical update on olanzapine treatment in schizophrenia and in the elderly Alzheimer's disease patients. In abstracts from the 35th annual NIHM New Clinical Drug Evaluation Unit Program, Orlando, FL: May 31-Jun 3, 1995.
25 Street J, Clark W, Ganno K. Olanzapine reduces psychosis and behavioral disturbances in the elderly [abstract]. Eur Neuropsychopharmacol 1999;9:S331.
26 Street J, Clark S, Kadam D, Mitan S, Juliar B, Feldman P, et al. Long-term efficacy of olanzapine in the control of psychotic and behavioural symptoms in Nursing Home Patients with Alzheimer's Dementia. Abstract presented lnternational Congress on Schizophrenia Research (ICSR) 2001.
27 Feldman P, Clark S, Sutton V, Sanger T, Breier A, Street J. Olanzapine in the prevention of psychosis among nursing home patients with behavioural disturbances associated with Alzheimer's disease. Abstract presented lnternational Congress on Schizophrenia Research (ICSR) 2001.
28 Mintzer J, Street J, Clark W, Sutton V, Feldman P, Roychowdhury S, et al. Olanzapine in the treatment of anxiety in patients with Alzheimer's disease. Abstract presented lnternational Congress on Schizophrenia Research (ICSR) 2001.
29 De Deyn P, Lemmens P, De Smedt G. Risperidone in the treatment of behavioral disturbances in dementia [abstract]. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology; Kamuela, Hawaii: Dec 8-12, 1997.
30 Zarate C, Baldessarini R, Siegel A. Risperidone in the elderly: a pharmacoepidemiologic study. J Clin Psychiatry 1997;58:311-7.
31 Katz I, Jeste D, Mintzer J, Clyde C, Napolitano J, Brecher M, for the Risperidone Study Group. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999;60:107-15.
32 Brecher M, Kane J, Okamoto A. Low frequeney of tardive dyskinesia in elderly patients with dementia exposed to risperidone for up to one year. Presented at the 151st annual meeting of tbc Arnerican Psychiatrie Association; Toronto, Ontario, Canada: May 30-June 5, 1998.
33 Cantillon M, Arvanitis L, Miller B. Quetiapine fumarate reduce aggression. In Programs and abstracts on new research for the 151st meeting of the American Psychiatryc Association, Toronto, Canada: May 30-June 4, 1998.
34 McManus D, Arvanitis L, Kowalcyk B, and the Seroquel Trial 48 Study Group. Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders. J Clin Psychiatry 1999;60:292-8.
35 Schneider L, Yeung P, Sweitzer D, Arvanitis L. Effects of seroquel on reducing Hostility and Psychosis in patients with Alzheimer's disease. Poster presented at the American Association's Annual Meeting, Washington DC: May 15-20, 1999.
36 Oberholzer A, Hendriksen C, Monsch A, Heierli B, Stahclin H. Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psychogeriat 1992;4:187-95.
37 Chengappa K, Baker R, Kreinbrook S, Adair D. Clozapine use in female geriatric patients with psychoses. J Geriatr Psychiatry Neurol 1995;8:12-5.
38 Tariot P. Treatment strategies for agitation and psychosis in dementia. J Clin Psychiatry 1996;57:21-9.
39 McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673-8.
40 Allen R, Walker Z, D'Ath P, Katona C. Risperidone for psychotic and behavioural symptoms in Lewy body dementia [letter]. Lancet 1995;346:185.
41 Chacko R, Hurley R, Jankovic J. Clozapine use in diffuse Lewy body disease. J Neuropsychiatry Clin Neurosi 1993;5:206-8.
42 Clark W, Street J, Sanger T, Breier A. Lewy Body-Like symptoms treated with olanzapine. Abstract presented lnternational Congress on Schizophrenia Research (ICSR) 2001.
43 O'Donnell B, Drachman D, Barnes H. Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 1992;5:45-52.
44 Cohen C, Gold D, Shulrnan K. Factors determining the decision to institutionalize dementing individuale: a prospective study. Gerontologist 1993;33:714-20.
45 Petrie W, Ban T, Berney S. Loxapine in psychogeriatrica: a placebo and standard-controlled clinical investigation. J Clin Psychopharmacol 1982;2:122-6.
46 Raskind M, Risse S, Lampe T. Dementia and antipsychotic drugs. J Clin Psychiatry 1987;48:16-8.
47 Schneider L, Pollock V, Lyness S. A metaanalysis of controlled trials of neuroleptic treatment in dementia patients. J Am Geriat Soc 1990;38:553-63.
48 Lanctot K, Best T, Mittmann N. Efficacy and safety of neuroleptics in behavioural disorders associated with dementia. J Clin Psychiatry 1998;59:550-61.
49 Daniel D. Antipsychotic Treatment of psychosis and Agitation in the elderly. J Clin Psychiatry 2000:61:49-52.
50 Alexopoulos G, Silver J, Kahn D. The Expert Consensus Guideline Series: Treatment of Agitation in Older Persons With Dementia [special report]. Postgrad Med 1998;1/3:1-88.
51 Arvanitis I, Rak I. The long term efficacy and safety of seroquel. Schizophrenia Res 1997;24:196-7.
52 Schneider L. Pharmacologic Management of Psychosis in dementia. J Clin Psychiatry 1999;60.
53 Barak Y, Wittenberg N, Naor S, Kutzuk D, Weizman A. Clozapine in Elderly psychiatric patients: tolerability, safety and efficacy. Compreh Psychiatry 1999;40:320-5.
54 Factor S, Brown D, Molho E, Podskalny C. Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology 1994;44:544-6.
55 Scholz E, Dichgans J. Treatment of drug-induced exogenous psychosis in Parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatr Neurol Sci 1985;235:60-4.
56 Wagner L, Defilippi J, Menza M, Sage J. Clozapine for treatment of psychosis in Parkinson's disease: chart review of 49 patients. J Neuropsychiatry Clin Neurosci 1996;8:276-80.
57 Ruggieri S, De Pandis M, Bonamartini A, Vacca L, Stocchi F. Low dose of clozapina in the treatment of dopaminergic psychosis in Parkinson's disease. Clin Neuropharmacol 1997;20:204-9.
58 Trosch RM, Friedman JH, Lannon MC, Pahwa R, Smith D, Seeberger LC, et al. Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience. Mov Disord 1998;13:377-82.
59 Parkinson Study group. Low dose of clozapine for the treatment of drug-induced psychosis in idiophatic Parkinson's disease. New Engl J Med 1999;340:757-63.
60 Linazasoro G, Marti Masso J, Suarez J. Nocturnal acatisia in Parkinson's disease: treatment with clozapine. Mov Disord 1993;8:171-4.
61 Juncos J. Clozapine treatment of parkinsonian pain syndromes (abstract). Mov Disord 1996;11:603-4.
62 Wolters E, Jansen E, Tuynman-Qua H, Bergmans P. Olanzapine in the treatment of dopaminomimetic psychosis. Neurology 1996;47:1085-7.
63 Jemenez-Jemenez F, Tallo-Baranco O, Orti Pareva. Olanzapine ca worsen parkinsonism. Neurology 1998;50:1183-4.
64 Friedman J, Goldstein S. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's Disease. Neurology 1998;50:1195-6.
65 Molho E, Factor S. Worsening of motor features of Parkitison's disease with olanzapine (abstract). Mov Disord 1998;13:256.
66 Gimenez-Roldan S, Mateo D, Navarro E, Gines M. Efficacy and safety of clozapina and olanzapina: an open-label study comparino two groups of Parkinson's disease patients with dopaminergic-induced psychosis. Parkinsonism and Related Disorders 2001;7:121-7.
67 Mayeux R. Parkinson's disease: a review of cognitive and psychiatric disorders. Neuropsychiat Neuropsych Behav Neurol 1990;3:3-14.
68 Meco G, Alessandria A, Bonifati V, Giustini P. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients [letter]. Lancet 1994;343:1370-1.
69 Workman R, Orengo C, Bakey A, Molinari V, Kunik M. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1997;9:594-7.
70 Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease [letter; comment]. Lancet 1994;344:681.
71 Friedman J, Ott R. Should risperidone be used in Parkinson's Disease? [letter]. J Neuropsychiatry Clin Neurosci 1998;10:473-4.
72 Rich S, Friedman J, Ott B. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995;56:556-9.
73 Rosebusch P, Mazurek M. Extrapyramidal side effects of risperidone (abstract). Neurology 1997;48:A325.
74 Evatt M, Jewart D, Juncos J. 'Seroquel' treatmento of psychosis in parkinsonism (abstract). Mov Disord 1996;11(5):595.
75 Juncos J, Evatt M, Jewart D. Long term effect of quetiapine fumarate in parkinsonism complicated by psychosis (abstract). Neurology 1998;50:A70-71.
76 Samantha J, Stacy M. Quetiapine in the treatment of hallucinations in advanced Parkinson's diseasc (abstract). Mov Disord 1998;13:274.
77 Fernandez H, Friedman J, Jacqucs C, et al. Quetiapine for drug-induced psychosis in Parkinson's disease. Mov Disord 1999;19:318.